|
|
Volumn 19, Issue 3, 2013, Pages 247-
|
|
Prevention measures
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;
PALIVIZUMAB;
UNCLASSIFIED DRUG;
VRC01;
ANTIVIRAL THERAPY;
CLINICAL TRIAL (TOPIC);
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HEALTH PROGRAM;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RESEARCH ETHICS;
RESPIRATORY SYNCYTIAL VIRUS INFECTION;
AFRICA;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEUTRALIZING;
CLINICAL TRIALS AS TOPIC;
HIV ANTIBODIES;
HIV INFECTIONS;
HUMANS;
INFANT;
INFANT, NEWBORN;
INFECTIOUS DISEASE TRANSMISSION, VERTICAL;
|
|
EID: 84875204292
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm.3139 Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|